Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Specimen Handling 146pembrolizumab 118Magnetic Resonance Spectroscopy 117Cyclophosphamide 113Biopsy 96fludarabine 88Nivolumab 52Carboplatin 51Cisplatin 47Gemcitabine 46Radiotherapy 41venetoclax 40Cetuximab 40fludarabine phosphate 39Paclitaxel 39Ipilimumab 34atezolizumab 33Fluorouracil 33Bevacizumab 32Oxaliplatin 27Leucovorin 27Dexamethasone 26durvalumab 25X-Rays 25Irinotecan 25Radiation 24Cytarabine 23Azacitidine 23Injections 22Temozolomide 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × voruciclib × 90 days × Clear all
NCT03547115 2026-03-17

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

MEI Pharma, Inc.

Phase 1 Terminated
84 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡